GynecologyGynecology2079-56962079-5831Consilium Medicum8036410.26442/20795696.2021.4.201091Research ArticleStress-protective effects of micronized progesterone in treatment of anxiety disorders in pregnant women after in vitro fertilisationTapilskayaNatalya I.<p>D. Sci. (Med.), Prof.</p>tapnatalia@yandex.ruhttps://orcid.org/0000-0001-5309-0087NekrasovMikhail S.<p>Graduate Student</p>nekrasov2013@inbox.ruKrikheliInna O.<p>Cand. Sci. (Med.)</p>iagmail@ott.ruhttps://orcid.org/0000-0002-5439-1727Ob'edkovaKsenia V.<p>Cand. Sci. (Med.)</p>iagmail@ott.ruGzgzyanAlexander M.<p>D. Sci. (Med.)</p>iagmail@ott.ruhttps://orcid.org/0000-0003-3917-9493KoganIgor Y.<p>D. Sci. (Med.), Prof., Corr. Memb. RAS</p>iagmail@ott.ruhttps://orcid.org/0000-0002-7351-6900GlushakovRuslan I.<p>Cand. Sci. (Med.)</p>glushakovruslan@gmail.comhttps://orcid.org/0000-0002-0161-5977Ott Research Institute of Obstetrics, Gynecology and ReproductologySaint Petersburg State Pediatric Medical UniversitySaint Petersburg State UniversityKirov Military Medical Academy2209202123434635317092021Copyright © 2021, Consilium Medicum2021<p><strong>Aim. </strong>To study a stress-protective efficacy of micronized progesterone (MP) in pregnant women with anxiety disorders after in vitro fertilisation (IVF).</p>
<p><strong>Materials and methods. </strong>We conducted a prospective, comparative open-label randomized trial in two IVF-clinics. A total of 98 pregnant women after IVF with anxiety disorders were recruited at the 9th week of pregnancy. Progesterone supplementation after IVF for luteal phase support was administered out until 9 weeks gestation. Then, after randomization, group 1 (n=35) received 400 mg per day of MP vaginally, group 2 (n=33) received 400 mg of MP orally, group 3 (n=30) was comparative for the other groups. The duration of progesterone treatment was 12 weeks. The Spielberger State Trait Anxiety Inventory (STAI), the Montgomerysberg depression rating scale (MADRS), Hospital Anxiety and Depression Scale (HADS), and the Epworth Sleepiness Questionnaires (ESQ) were used to compare maternal mood at 9 weeks (day of randomization) after delivery and at 283, 565, 847 days after randomization.</p>
<p><strong>Results. </strong>The mean STAI sumscore in MP-groups was significantly lower than in group 3 starting from day 565 and continued until the end of the study. There were no significant differences between vaginal and oral administration of progesterone. There were no significant differences between the mean sumscores when questioning on the HADS, MADRS and ESQ.</p>
<p><strong>Conclusion. </strong>Prolonged use of MP in pregnant women with anxiety disorders led to the prevention of manifestations of an increase in anxiety and depression. The stress-protective and neuromodulating properties of MP can determine additional indications for its prolonged administration in women with anxiety disorders and/or premorbid history.</p>micronized progesteronestress protectionpregnancyassisted reproductive technologiesмикронизированный прогестеронстрессопротекциябеременностьвспомогательные репродуктивные технологии[Quenby S, Gallos ID, Dhillon-Smith RK, et al. Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss. Lancet. 2021;397(10285):1658-67. DOI:10.1016/S0140-6736(21)00682-6][Brier N. Understanding and managing the emotional reactions to a miscarriage. Obstet Gynecol. 1999;93:151-5. DOI:10.1016/s0029-7844(98)00294-4][Abu-Musa AA, Kobeissi L, Hannoun AB, Inhorn MC. Effect of war on fertility: a review of the literature. Reprod Biomed Online. 2008;17(Suppl. 1):43-53. DOI:10.1016/s1472-6483(10)60189-7][Akesson B. Addressing the psychosocial needs of pregnant women affected by war: program approaches and program gaps. Canada's Journal on Refugees. 2008;25(1):55-9. DOI:10.25071/1920-7336.21397][Wainstock T, Lerner-Geva L, Glasser S, et al. Prenatal stress and risk of spontaneous abortion. Psychosom Med. 2013;75:228-35. DOI:10.1097/PSY.0b013e318280f5f3][Traylor CS, Johnson J, Kimmel MC, Manuck TA. Effects of psychological stress on adverse pregnancy outcomes and non-pharmacologic approaches for reduction: an expert review. Am J Obstet Gynecol MFM. 2020;2(4):100229. DOI:10.1016/j.ajogmf.2020.100229][Kapur J, Joshi S. Progesterone modulates neuronal excitability bidirectionally. Neurosci Lett. 2021;744:135619. DOI:10.1016/j.neulet.2020.135619][Piette PCM. The pharmacodynamics and safety of progesterone. Best Pract Res Clin Obstet Gynaecol. 2020;69:13-29. DOI:10.1016/j.bpobgyn.2020.06.002][Тапильская Н.И. Роль иммунной системы в патогенезе невынашивания беременности. Предпосылки для фармакологической коррекции. Обзоры по клинической фармакологии и лекарственной терапии. 2002;1(2):15-26 [Tapilskaya NI. Rol' immunnoi sistemy v patogeneze nevynashivaniia beremennosti. Predposylki dlia farmakologichekoi korrektsii. Obzory po klinicheskoi farmakologii i lekarstvennoi terapii. 2002;1(2):15-26 (in Russian)].][Diviccaro S, Cioffi L, Falvo E, et al. Allopregnanolone: an overview on its synthesis and effects. J Neuroendocrinol. 2021;2021:e12996. DOI:10.1111/jne.12996][Liu A, Margaill I, Zhang S, et al. Progesterone receptors: a key for neuroprotection in experimental stroke. Endocrinology. 2012;153(8):3747-57. DOI:10.1210/en.2012-1138][Lerouet D, Marchand-Leroux C, Besson VC. Neuropharmacology in traumatic brain injury: from preclinical to clinical neuroprotection? Fundam Clin Pharmacol. 2021;35(3):524-38. DOI:10.1111/fcp.12656][Piette P. The history of natural progesterone, the never-ending story. Climacteric. 2018;21(4):308-14. DOI:10.1080/13697137.2018.1462792][Guennoun R, Zhu X, Frechou M, et al. Steroids in stroke with special reference to progesterone. Cell Mol Neurobiol. 2019;39(4):551-68. DOI:10.1007/s10571-018-0627-0][Djakocic E, Rakic S. Depression, anxiety, and stress after preterm delivery: role of previous progesterone therapy. Clin Exp Obstet Gynecol. 2018;45(2):214-7. DOI:10.12891/ceog3820.2018][Савельева Г.М., Аксененко В.А., Андреева М.Д., и др. Терапия привычного выкидыша микронизированным прогестероном (результаты многоцентрового исследования Тристан-1). Акушерство и гинекология. 2017;11:44-55 [Saveleva GM, Aksenenko VA, Andreeva MD, et al. Micronized progesterone therapy of recurrent pregnancy loss (results of multicenter Tristan-1 study). Akush Ginekol (Mosk). 2017;11:44-55 (in Russian)]. DOI:10.18565/aig.2017.11.44-55][Савельева Г.М., Аксененко В.А., Андреева М.Д., и др. Исходы второй половины беременности у пациенток с привычным выкидышем в анамнезе (результаты многоцентрового исследования Тристан-2). Акушерство и гинекология. 2018;8:111-21 [Saveleva GM, Aksenenko VA, Andreeva MD, et al. Outcomes of the second half of pregnancy in patients with recurrent pregnancy loss (results of multicenter study of Tristan-2). Akush Ginekol (Mosk). 2018;8:111-21 (in Russian)]. DOI:10.18565/aig.2018.8.111-121][Caufriez A, Leproult R, L'Hermite-Baleriaux M, et al. Progesterone prevents sleep disturbances and modulates GH, TSH, and melatonin secretion in postmenopausal women. J Clin Endocrinol Metab. 2011;96(4):E614-23. DOI:10.1210/jc.2010-2558][Schüssler P, Klug M, Adamczyk M, et al. Sleep after intranasal progesterone vs. zolpidem and placebo in postmenopausal women – a randomized, double-blind cross over study. Psychoneuroendocrinology. 2018;92:81-6. DOI:10.1016/j.psyneuen.2018.04.001][Atik RB, Christiansen OB, Elson J, et al. ESHRE guideline: recurrent pregnancy loss. Human Reproduction Open. 2018;2:1-12. DOI:10.1093/hropen/hoy004.]